# Arnie Oronsky

> Arnie Oronsky is a Series A investor at InterWest Partners backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [InterWest Partners](https://shizune.co/investors/profile/interwest-partners)
- Location: San Francisco, United States
- Total investments: 7
- Last investment: Dec 2014
- Lead investor: 43%
- Last updated: Aug 2026

Arnie Oronsky is a Series A investor at InterWest Partners in San Francisco focused on Health Care and Biotechnology. Dr. Arnie Oronsky has been with InterWest's life sciences team since 1994. He is a board member of Amplimmune, Applied Genetic Technologies Corporation (AGTC), Arcion, Drais Pharmaceuticals, Dynavax Technologies (DVAX), Integrated Diagnostics, MacroGenics, RadioRX, TESARO and USDS.As a Ph.D. in immunology and senior lecturer at theDepartment of Medicine at Johns Hopkins Medical School, Arnie brings a deep understanding of medical research to finding and investing in successful life sciences companies.Prior to joining InterWest, Arnie was vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs.Arnie received a Ph.D. in immunology from Columbia University and has published more than 125 articles in scientific journals.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 86% |
| Biotechnology | 6 | 86% |
| Biopharma | 2 | 29% |
| Health Diagnostics | 2 | 29% |
| Genetics | 1 | 14% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Series B | 2 | 29% |
| Funding Round | 2 | 29% |
| Seed | 1 | 14% |
| Series D | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PMV Pharmaceuticals | PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. | $30M | Series A | Dec 02, 2014 |  |
| AGTC | Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused bybroken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide. | $37.5M | Series B | Nov 19, 2012 |  |
| TESARO | Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for thetreatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts. | $101M | Series B | Jun 21, 2011 |  |
| Integrated Diagnostics | The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The companyplans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules. | $30M | Series A | Oct 14, 2009 |  |
| AGTC | Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused bybroken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide. | $11.8M |  | Jun 09, 2009 |  |
| MacroGenics | MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company'sFc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.The company was founded in 2000 and is headquartered in Rockville, Maryland. | $25M | Series D | Oct 23, 2008 |  |
| MacroGenics | MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company'sFc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.The company was founded in 2000 and is headquartered in Rockville, Maryland. | $12.6M |  | Jun 07, 2002 |  |

7 of 7 investments shown.

## Co-investors
- [Alexandria Real Estate Equities](https://shizune.co/investors/profile/alexandria-real-estate-equities) — VC Fund, 2 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 2 deals together
- [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners) — VC Fund, 2 deals together
- [MedImmune Ventures](https://shizune.co/investors/profile/medimmune-ventures) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Mitsubishi UFJ](https://shizune.co/investors/profile/bank-of-tokyo-mitsubishi-ufj) — VC Fund, 1 deal together

## About InterWest Partners

VC Fund · Menlo Park, United States

InterWest invests an average of about $7 - 15 million over the span of their involvement with each company in their portfolio. They invest in companies through the full range of venture investment stages, and investments may be staged over several rounds of financing. Although they generally begin their involvement in the early stages of acompany's development, they pursue attractive opportunities based on their individual merits rather than their investment stage.

5 contacts available at InterWest Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Doug Fisher | Executive in Residence & Partner | https://shizune.co/investors/profile/doug-fisher |
| Arnie Oronsky | Managing Director | https://shizune.co/investors/profile/arnold-oronsky |
| Charline Gauthier | Executive-in-Residence | https://shizune.co/investors/profile/charline-gauthier |
| Karen Wilson | CFO | https://shizune.co/investors/profile/karen-wilson |
| Katie Passalacqua | Controller | https://shizune.co/investors/profile/katie-passalacqua |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Arnie Oronsky invest in?

Arnie Oronsky invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Arnie Oronsky last invest?

The most recent investment recorded for Arnie Oronsky closed in Dec 2014. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co